대한뉴팜

The company announced on July 13 the results of a comprehensive corporate tax investigation through an official disclosure and completed the full payment of corporate tax amounting to 15.67 billion KRW on July 31. After completing the tax payment, the company plans to file an appeal and a petition for review in accordance with the Framework Act on National Taxes. Taking this integrated tax audit as an opportunity, Daehan New Pharm is pursuing greater internal soundness by innovating its management systems and focusing on research and development. The company’s sales grew by 7.8% in 2012 and 18.1% in 2013, maintaining an impressive annual growth rate of over 20% for three consecutive years starting in 2014. This strong growth has been driven by a well-structured product portfolio and differentiated therapeutic solutions that established Daehan New Pharm as a leader in the obesity and wellness pharmaceutical segments. In addition, continuous R&D efforts have enabled the company to expand its product lines into chronic disease treatments such as hypertension and hyperlipidemia. Since 2013, the company has also been investing aggressively in biotechnology, establishing a serum-free culture medium production facility in the Hyangnam Pharmaceutical Complex to provide customized media to clients. The company’s Central R&D Center in Hyangnam and its affiliated research institute in Osong are collaborating closely to carry out various bio-research projects. Daehan New Pharm’s focus on biotechnology stems from its strategy to combine its established strengths in obesity and wellness pharmaceuticals with the bio sector, thereby creating business synergy and new growth engines for the future. To further strengthen sales and R&D, the company continues to steadily expand its recruitment each year. Notably, all 341 employees at Daehan New Pharm are full-time regular employees—a policy aligned with the company’s management philosophy of fostering a “warm and inclusive workplace.” Every member of the organization is dedicated to sustaining the company’s strong growth trajectory and will continue to drive the momentum of innovation that has been built over the years.

Daehan New Pharm has recorded a 23% year-over-year growth rate in the obesity treatment market, continuing to strengthen its leadership position. The company has achieved sustained annual sales growth of over 20% for the past three years, driven by the continued launch of reimbursable products, increased market share of oral obesity drugs, and expansion into the non-reimbursable injectable treatment segment. Among these, oral obesity drugs have shown particularly steady growth. Daehan New Pharm’s representative oral anti-obesity products include appetite suppressants such as Phentin (Phendimetrazine), Phestin (Phentermine), and Phtym (Phentermine HCl), as well as the fat absorption inhibitor Zerofat (Orlistat), which the company co-markets with Mothers Pharmaceutical. In addition, Daehan New Pharm offers a wide range of obesity-related therapeutic products, collectively accounting for over 40% of the anti-obesity drug market share. Following a decline in obesity surgeries such as gastric banding and sleeve gastrectomy after the Shin Hae-chul incident, interest in combined pharmacological and exercise-based therapies has grown. As a result, the oral obesity drug market has steadily expanded, reaching approximately 100 billion KRW in 2016 according to IMS data, and continues to show growth momentum. Although newer drugs such as Belviq (Ildong Pharmaceutical) and Contrave (Kwangdong Pharmaceutical) have contributed to market expansion, traditional appetite suppressants containing phendimetrazine or phentermine and fat absorption inhibitors still hold a dominant share of the obesity market. Utilizing its extensive experience in obesity prescription marketing, Daehan New Pharm continues to expand its trading network and revenue. The company has also developed therapeutics to alleviate side effects associated with oral obesity medications, driving rapid sales growth. In the first half of this year, Daehan New Pharm’s oral obesity drug sales achieved an impressive 23% increase compared to the same period last year. Moving forward, the company plans to further strengthen brand recognition for products such as Phentin, Fastin, and Topin and expand its market share through its 3S strategy—self-control, self-confidence, and satisfaction—designed to meet the needs of both customers and patients.

Daehan New Pharm has launched its newly redesigned website on the 6th. In response to the steady increase in website traffic driven by the company’s continuous sales growth, Daehan New Pharm carried out a renewal project to make the website more accessible, convenient, and user-friendly. In the renewal, the product categories have been reorganized into four main sections—Human Pharmaceuticals, Veterinary Pharmaceuticals, Biopharmaceuticals, and Export Pharmaceuticals—allowing visitors to easily browse Daehan New Pharm’s product lineup. Additionally, a new communication feature has been introduced, enabling customer inquiries to be directly forwarded in real time to the responsible departments for prompt responses. The company also plans to sequentially launchd versions of its mobile and English websites in the near future.

The company’s newly launched non-reimbursable injectable products have successfully established a firm position in the market, becoming a key driver of new revenue growth. In April of last year, Daehan New Pharm launched “New-DN Injection” formulated with Polydeoxyribonucleotide (commonly known as the salmon DNA ingredient). Later, in December, the company signed an exclusive sales agreement with HaspiCare Co., Ltd. to distribute the mistletoe injection “Iscador (ISCADOR).” “New-DN Injection” is primarily used in departments such as anesthesiology and pain medicine, orthopedics, and dermatology as an adjunct therapy for pain treatment and aesthetic procedures. “Iscador,” an immune-boosting mistletoe extract used as an anticancer adjuvant, is mainly administered in convalescent hospitals and oncology clinics. Although the non-reimbursable nutritional injection market has stagnated due to oversupply following the release of generic products, Daehan New Pharm has continued to expand and restructure its portfolio by diversifying into new therapeutic areas such as pain relief and anticancer adjuvant treatments. In addition, in April this year, the company began exclusive domestic sales of HA fillers—“Qugel,” “Flore,” and “Cheongaan”—manufactured by Korea BNC Co., further expanding its reach into the filler market. Among its 30 non-reimbursable injectable products, the newly introduced “New-DN Injection” “Iscador,” and HA filler lines have achieved a combined 30% share of total injectable sales within just one year of launch. As the non-reimbursable injection market continues to evolve, Daehan New Pharm plans to lead market transformation by continuously introducing differentiated and innovative new products.

Daehan New Pharmed by global veterinary vaccine leader HIPRA for its strong cattle product sales network in Korea - The only bovine mastitis vaccine registered with the European Medicines Agency (EMA), proven for safety and efficacy, providing dual protection against two major pathogens - “A significant contribution to preventing chronic dairy farm diseases and advancing Korea’s veterinary and dairy industries” Daehan New Pharm has signed an exclusive sales agreement with global veterinary vaccine company HIPRA for “Hipra Startvac,” a multivalent vaccine developed to combat bovine mastitis, and has commenced product distribution in Korea. Through this partnership, Daehan New Pharm will begin full-scale domestic supply of “Hipra Startvac,” targeting bovine mastitis—a chronic, recurring disease in dairy farms. “Hipra Startvac” prevents infection caused by Staphylococcus aureus and Escherichia coli, the two major pathogens responsible for bovine mastitis. As the first bovine mastitis vaccine approved by the European Medicines Agency (EMA), it has been verified for both safety and efficacy and is currently registered and sold in over 50 countries worldwide. No side effects such as abscess formation or somatic cell count increases have been reported, and clinical trials conducted on local dairy farms in Gyeonggi Province confirmed an absence of adverse reactions. Polysaccharide biofilms formed by Staphylococcus aureus and coagulase-negative staphylococci (CNS) enable bacteria to adhere to mammary glands, inducing antibiotic resistance and high pathogenicity. “Hipra Startvac” is the only vaccine proven to inhibit and prevent this biofilm formation, thereby suppressing bacterial proliferation and neutralizing adhesion factors to effectively prevent mastitis. Unlike existing domestic competitors, “Hipra Startvac” provides cross-protection not only against S. aureus and E. coli but also against CNS and coliform bacteria—making it a truly multivalent vaccine. The total Korean vaccine market is estimated at approximately 300 billion KRW, with foreign companies accounting for 60–70% of the domestic livestock vaccine segment. This exclusive sales agreement marks Daehan New Pharm’s first entry into the vaccine market, and with its strong presence in the cattle segment, the company anticipates sustained growth in mastitis vaccine sales. Unlike conventional vaccines, “Hipra Startvac” has no post-injection side effects and is recommended for use even during lactation. The optimal vaccination schedule involves intramuscular injection in the neck 45 and 10 days before calving and at 50 days after calving, effectively reducing the risk of infection, economic losses, and mastitis incidence. Kim Myung-hwi, Head of HIPRA Korea, stated, “We are delighted to grant Daehan New Pharm exclusive distribution rights for ‘Hipra Startvac,’ a vaccine with exceptional efficacy compared to competitors. Daehan New Pharm’s strong nationwide distribution network for cattle products played a key role in our decision. We hope this vaccine will help establish a preventive dairy farming culture in Korea and serve as a definitive solution to mastitis, a chronic challenge for dairy producers.” Following this agreement, Daehan New Pharm plans to collaborate with HIPRA headquarters to provide on-site bacterial diagnostic systems and related services for dairy farms seeking to implement advanced diagnostic infrastructures.

In January 2017, Daehan New Pharm launched “Pleincell,” a hyaluronic acid (HA) filler containing lidocaine. The name “Pleincell,” derived from the French word meaning “to be full,” represents the product’s ability to deliver natural volume. It features a patented cross-linking technology that creates a uniform HA particle structure, while its low residual BDDE content minimizes toxicity. Additionally, it is completely dissolvable with hyaluronidase, ensuring excellent safety and reversibility. A filler is a medical device that restores skin tissue volume and improves wrinkles or facial contours through injection beneath the skin. A variety of fillers are currently available, including those based on HA, PLA, and PCA. The HA filler market alone has surpassed 100 billion KRW and continues to grow by more than 10% annually. Leveraging its strong brand recognition in wellness and beauty pharmaceuticals, Daehan New Pharm is actively reviewing the introduction of diverse facial aesthetic treatments and medical devices to expand its presence in this high-growth segment.

Executive Director Jeong Jin-tae Leads New Forage Business Initiative Pursuing a New Forage Business to Create a Growth EngineClose Field Engagement – Maximizing Synergy with Existing Animal Health Business After completing a 30-year career with the National Agricultural Cooperative Federation (NACF), Executive Director Jeong Jin-tae began a new chapter at Daehan New Pharm on the 1st of last month. “I may have left the cooperative, but its spirit still runs through me,” Jeong said, expressing his commitment to continue contributing to the livestock industry and supporting livestock farmers through his role at Daehan New Pharm. He added, “Customer growth is company growth. With a mindset that consumers and businesses are one, we aim to build a business model of mutual prosperity.” Jeong explained that Daehan New Pharm is now advancing into the forage business as a new growth initiative.“I was in charge of forage operations for quite a long time at the NACF. With that experience and know-how, I’m confident that the forage business can thrive here as well. We’re already seeing tangible results, including initial sales,” he said, while emphasizing that profitability alone is not the goal. “Our aim is to supply high-quality forage at reasonable prices to enhance the productivity of livestock farmers and ease their production cost burden,” Jeong noted.He added, “For Daehan New Pharm, this means providing more diversified customer services. The forage business will not only become a new growth engine but also generate synergy with our existing animal pharmaceutical operations.” Jeong underscored his field-oriented approach: “I visit farms daily and listen directly to what they need. Later this month, I will travel to Australia to identify better forage products that meet farmers’ demands. There, I plan to carefully assess quality and pricing to ensure competitiveness.” Having embarked on what he calls his “second life chapter” at Daehan New Pharm, Jeong admitted that adapting to the corporate business culture was initially unfamiliar but quickly became meaningful.“I’ve fully adjusted and now have a clear goal—to devote all my remaining passion and ability to elevating Daehan New Pharm into Korea’s leading animal pharmaceutical company,” he said with conviction. Reported by Kim Young-gil, Livestock Cooperative NewsOriginal article: http://www.chuksannews.co.kr/news/article.html?no=104640

- Achieved cumulative Q3 sales of 79.7 billion KRW and operating profit of 8.6 billion KRW, representing over 20% year-on-year growth- Sustained strong performance across all major business sectors, including pharmaceuticals, wellness, and veterinary medicine- “We expect to maintain this growth momentum into Q4, targeting annual sales of 110 billion KRW and operating profit of 12 billion KRW” Daehan New Pharm continued its double-digit growth for the 17th consecutive quarter, maintaining an average sales increase of around 20%. According to consolidated results for the third quarter, the company reported cumulative sales of 79.7 billion KRW and operating profit of 8.6 billion KRW. Compared to the same period last year, sales rose by 19.1% and operating profit by 17.4%, marking the 17th consecutive quarter of double-digit growth since Q3 2012—a record of consistent performance that holds strong significance. This consistent growth stems from balanced expansion across all business divisions. The pharmaceutical division has strengthened market dominance through differentiated business models such as lyophilized injectable development, cutting-edge clinical protocols, and customized solution-based sales strategies. The wellness division also played a key role by successfully leading new product initiatives and expanding its portfolio. In the veterinary medicine division, despite sluggish market conditions, Daehan New Pharm achieved approximately 10% year-on-year sales growth through customer-centered product development and on-site engagement, breaking the notion that the market has reached maturity and limited growth potential. Within the human pharmaceutical portfolio, new products such as Newtor Tab.—a cardiovascular therapy—and New-DN Injection., an injectable used for post-skin graft wound care, have gained robust market traction. These new products now account for over 30% of total sales, further strengthening the company’s overall product portfolio. Daehan New Pharm CEO Bae Gun-woo commented, “In our international operations, we are reinforcing partnerships with key markets such as Russia and China to achieve our global business objectives. We are also actively expanding into new markets including Mongolia and Australia, further building on the capabilities that earned us the ‘10 Million Dollar Export Tower’ award last year.” He added, “Our sustained growth has been driven by differentiated solution development, creative sales strategies, and strong human capital. We are confident of reaching 110 billion KRW in annual sales and 12 billion KRW in operating profit in 2016. Looking ahead, we will continue this growth trajectory by strengthening R&D for improved pharmaceuticals, developing new growth engines in the bio and global sectors, and enhancing the core competencies of our key talent.”

Last month, Daehan New Pharm's CEO Bae Gun-woo, Overseas Business Director Kim Young-dong, and the Mongolian exclusive distributor partner City Medlux appeared on a segment called "Let's Have a Cup of Tea," a morning program on Mongolia's UBS broadcast. They introduced three products: Luthione Injection, Cindella Injection, and Vitamin C Injection. Daehan New Pharm signed an exclusive supply agreement with Mongolia’s City Medlux LLC for these three products and completed pharmaceutical registration last month, planning to conduct active marketing and sales efforts.This broadcast is expected to enhance Daehan New Pharm’s reputation and contribute to increasing sales in the Mongolian market. The company also plans to gradually expand from pharmaceuticals to medical devices and cosmetics with products such as Liporase, Mesocartin, fillers, and Luthione cosmetics.